Literature DB >> 20331971

Functional availability of gamma-herpesvirus K-cyclin is regulated by cellular CDK6 and p16INK4a.

Hidenori Yoshioka1, Kohji Noguchi, Kazuhiro Katayama, Junko Mitsuhashi, Satoshi Yamagoe, Masahiro Fujimuro, Yoshikazu Sugimoto.   

Abstract

Viral K-cyclin derived from Kaposi's sarcoma-associated herpesvirus is homologous with mammalian D-type cyclins. Here, we demonstrated the regulatory mechanisms for K-cyclin function and degradation in human embryonic kidney HEK293 and primary effusion lymphoma JSC-1 cell lines. Proteasome inhibitor MG132 treatment induced an accumulation of ubiquitinated K-cyclin in these cells, and co-expression of CDK6 prevented K-cyclin ubiquitination. Also K-cyclin mutants incompetent for CDK6-binding were destabilized by proteasome pathway. Furthermore, silencing of p16INK4a promoted K-cyclin-CDK6 complex formation and hence induced K-cyclin-associated kinase activity in HEK293 cells. These observations indicate that CDK6-bound K-cyclin is functionally stable but monomeric K-cyclin is targeted to ubiquitin-dependent degradation pathway in these cells. Our data suggest that the balance between CDK6 and p16INK4a regulates the availability of functional K-cyclin in human cells. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20331971     DOI: 10.1016/j.bbrc.2010.03.110

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Viral cyclin promotes KSHV-induced cellular transformation and tumorigenesis by overriding contact inhibition.

Authors:  Tiffany Jones; Suzane Ramos da Silva; Roble Bedolla; Fengchun Ye; Fuchun Zhou; Shou-Jiang Gao
Journal:  Cell Cycle       Date:  2014-01-13       Impact factor: 4.534

2.  Effect of AKT3 expression on MYC- and caspase-8-dependent apoptosis caused by polo-like kinase inhibitors in HCT 116 cells.

Authors:  Yuma Nonomiya; Kohji Noguchi; Noritaka Tanaka; Takahiro Kasagaki; Kazuhiro Katayama; Yoshikazu Sugimoto
Journal:  Cancer Sci       Date:  2016-12-19       Impact factor: 6.716

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.